Aratana Therapeutics Inc (PETX)

7.28
0.03 0.41
NASDAQ : Health Care
Prev Close 7.25
Open 7.49
Day Low/High 7.20 / 7.49
52 Wk Low/High 2.56 / 19.99
Volume 194.48K
Avg Volume 354.90K
Exchange NASDAQ
Shares Outstanding 42.96M
Market Cap 311.44M
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Commit To Buy Aratana Therapeutics At $5, Earn 6.6% Annualized Using Options

Commit To Buy Aratana Therapeutics At $5, Earn 6.6% Annualized Using Options

Investors eyeing a purchase of Aratana Therapeutics, Inc stock, but cautious about paying the going market price of $7.32/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the February 2018 put at the $5 strike, which has a bid at the time of this writing of 20 cents.

Non-FANG Stocks May Finally Get Some Love

Non-FANG Stocks May Finally Get Some Love

Tech meltdown provides an opportunity for rotation into undervalued sectors.

Liking the Look of Some of These Pullbacks

Liking the Look of Some of These Pullbacks

This corrective action has me feeling optimistic about some new opportunities.

Biotech Movers: Aratana Offering Priced Below Market, Shares Fall

Biotech Movers: Aratana Offering Priced Below Market, Shares Fall

Aratana Therapeutics, Trevena and Sangamo Therapeutics were among the biotech stock movers in premarket trading on Thursday.

Short Interest Expands By 24% For PETX

The most recent short interest data has been released for the 03/31/2017 settlement date, which shows a 882,728 share increase in total short interest for Aratana Therapeutics, Inc , to 4,576,114, an increase of 23.90% since 03/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

First Week of PETX November 17th Options Trading

Investors in Aratana Therapeutics, Inc saw new options become available this week, for the November 17th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 235 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of A Class Action On Behalf Of Shareholders Of Aratana Therapeutics, Inc. - Lead Plaintiff Deadline Of April 7, 2017

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Aratana Therapeutics, Inc.

PETX INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of Commencement Of A Class Action Involving Aratana Therapeutics, Inc. And A Lead Plaintiff Deadline Of April 7, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Aratana Therapeutics, Inc.

Two Small Growth Stories

Two Small Growth Stories

An update on two small-caps that reported earnings.

DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In Aratana Therapeutics, Inc. To Contact The Firm

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of...

Aratana Therapeutics Becomes Oversold (PETX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Biotech Premarket Movers: Editas, Amphastar, Aratana, Pacira

Biotech Premarket Movers: Editas, Amphastar, Aratana, Pacira

Editas Medicine, Amphastar Pharmaceuticals, Aratana Therapeutics and Pacira Pharmaceuticals were among the biotech stock movers in premarket trading on Tuesday.

Shark Bites: Market Needs a Bounce in Its Step

Shark Bites: Market Needs a Bounce in Its Step

Biotechnology continues to be a bright spot.

PETX INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Aratana Therapeutics, Inc. And A Lead Plaintiff Deadline Of April 7, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Aratana Therapeutics, Inc.

3 Small Biotechs That Still Have Upside

3 Small Biotechs That Still Have Upside

Companies developing drugs for cancer, eye problems and pets -- offer untapped value.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Has Commenced A Class Action On Behalf Of Shareholders Of Aratana Therapeutics, Inc. - Lead Plaintiff Deadline Of April 7, 2017

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Aratana Therapeutics, Inc.

Commit To Buy Aratana Therapeutics At $5, Earn 17.2% Annualized Using Options

Investors eyeing a purchase of Aratana Therapeutics, Inc stock, but tentative about paying the going market price of $6.49/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the May put at the $5 strike, which has a bid at the time of this writing of 20 cents.